aiSLE® DX Disease Activity Index
Systemic Lupus Erythematosus (SLE)
CommercialActive
Key Facts
About Progentec Diagnostics
Progentec Diagnostics is pioneering a data-driven, proactive approach to managing autoimmune diseases by integrating molecular diagnostics (proteomics) with digital biomarkers and remote monitoring. Its flagship aiSLE® DX tests, available through Mayo Clinic Laboratories, predict lupus flare risk up to 12 weeks in advance. The company also operates a significant digital patient community and research platform (LupusCorner) and is expanding its pipeline into MS and other autoimmune conditions. Its business model leverages diagnostic test revenue and digital tools to improve patient outcomes and support decentralized clinical research.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 2 |
| Nipocalimab | johnson-and-johnson-innovative-medicine | Phase 3 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| IFNα Kinoid (IFN-K) | Neovacs | Phase IIb |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Internal Program | BenevolentAI | Preclinical |
| Telitacicept (RC18) | RemeGen | Approved |
| Cenerimod | Ono Pharmaceutical | Phase 3 |